Alteration of Leptin and Adiponectin in Multistep Colorectal Tumorigenesis

  • Saetang, Jirakrit (Department of Biomedical Science, Faculty of Medicine, Prince of Songkla University) ;
  • Boonpipattanapong, Teeranut (Tumor Biology Research Unit, Faculty of Medicine, Prince of Songkla University) ;
  • Palanusont, Anuwat (Tumor Biology Research Unit, Faculty of Medicine, Prince of Songkla University) ;
  • Maneechay, Wanwisa (Central Research Laboratory, Faculty of Medicine, Prince of Songkla University) ;
  • Sangkhathat, Surasak (Department of Biomedical Science, Faculty of Medicine, Prince of Songkla University)
  • Published : 2016.06.01


Background: There is an established link between obesity related metabolic derangement and colorectal cancer development. Recently, we developed a metabolic-colorectal cancer risk score. In this follow-up study, we studied its association with colorectal neoplasm by measuring two major metabolic syndrome biomarkers, leptin and adiponectin. Objectives: To evaluate the serum levels of leptin and adiponectin in patients with colorectal polyps and colorectal cancer and to determine any correlation with metabolic risk score. Results: In total, 130 individuals were studied: 30 controls without colonic pathology, 18 with colonic adenoma (CAP), and 82 with colorectal adenocarcinoma (CRC, 17 cases of T1-2 and 65 cases of T3-4). The metabolic risk scores in CAP and T1-2 CRC were higher than those in the controls and T3-4 CRC cases. There were no statistically significant differences in leptin levels among CAPs, CRCs, and controls. Both leptin and adiponectin levels reflected differences in body mass index and metabolic risk scores. Cases in the CAP group and early T-stage CRC groups had lower adiponectin levels (14.03 and 13.01 mg/ml, respectively) than the no polyps group (19.5mg/ml, p = 0.03). The average serum adiponectin level in the invasive cancer group (18.5 ng/ml) was comparable with that of the control group. Conclusions: The level of serum adiponectin was positively correlated with the metabolic risk score. Decreased serum adiponectin was significantly associated with the development of colorectal adenoma and early stage colorectal carcinoma.



Supported by : Thailand Research Fund


  1. Alberti KG, Zimmet P, Shaw J (2006). Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med, 23, 469-80.
  2. Aleksandrova K, Jenab M, Bueno-de-Mesquita HB, et al (2014). Biomarker patterns of inflammatory and metabolic pathways are associated with risk of colorectal cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Eur J Epidemiol, 29, 261-75.
  3. Arnold CN, Goel A, Blum HE, Boland CR (2005). Molecular pathogenesis of colorectal cancer: implications for molecular diagnosis. Cancer, 104, 2035-47.
  4. Attele AS, Shi ZQ, Yuan CS (2002). Leptin, gut, and food intake. Biochem Pharmacol, 63, 1579-83.
  5. Bonakdaran S, Kharaqani B (2014). Association of serum uric acid and metabolic syndrome in type 2 diabetes. Curr Diabetes Rev, 10, 113-7.
  6. Cowley MA, Smart JL, Rubinstein M, et al (2001). Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature, 411, 480-4.
  7. Dalamaga M, Diakopoulos KN, Mantzoros CS (2012). The role of adiponectin in cancer: a review of current evidence. Endocr Rev, 33, 547-94.
  8. Doyle SL, Donohoe CL, Lysaght J, Reynolds JV (2012). Visceral obesity, metabolic syndrome, insulin resistance and cancer. Proc Nutr Soc, 71, 181-9.
  9. Erarslan E, Turkay C, Koktener A, et al (2009). Association of visceral fat accumulation and adiponectin levels with colorectal neoplasia. Dig Dis Sci, 54, 862-8.
  10. Gialamas SP, Sergentanis TN, Antonopoulos CN, et al (2013). Circulating leptin levels and risk of colorectal cancer and adenoma: a case-control study and meta-analysis. Cancer Causes Control, 24, 2129-41.
  11. Gonullu G, Kahraman H, Bedir A, Bektas A, Yucel I (2010). Association between adiponectin, resistin, insulin resistance, and colorectal tumors. Int J Colorectal Dis, 25, 205-12.
  12. Green ED, Maffei M, Braden VV, et al (1995). The human obese (OB) gene: RNA expression pattern and mapping on the physical, cytogenetic, and genetic maps of chromosome 7. Genome Res, 5, 5-12.
  13. Greene FL (2002). The american joint committee on cancer: updating the strategies in cancer staging. Bull Am Coll Surg, 87, 13-5.
  14. Hardwick JC, Van Den Brink GR, Offerhaus GJ, Van Deventer SJ, Peppelenbosch MP (2001). Leptin is a growth factor for colonic epithelial cells. Gastroenterol, 121, 79-90.
  15. Kadowaki T, Yamauchi T (2005). Adiponectin and adiponectin receptors. Endocr Rev, 26, 439-51.
  16. Kritsanasakul A, Boonpipattanapong T, Wanitsuwan W, et al (2012). Impact of lymph node retrieval on surgical outcomes in colorectal cancers. J Surg Oncol, 106, 238-42.
  17. Kumor A, Daniel P, Pietruczuk M and Malecka-Panas E (2009). Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis, 24, 275-81.
  18. Lubkowska A, Radecka A, Bryczkowska I, et al (2015). Serum Adiponectin and Leptin Concentrations in Relation to Body Fat Distribution, Hematological Indices and Lipid Profile in Humans. Int J Environ Res Public Health, 12, 11528-48.
  19. Lukanova A, Soderberg S, Kaaks R, Jellum E, Stattin P (2006). Serum adiponectin is not associated with risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev, 15, 401-2.
  20. Nakajima TE, Yamada Y, Hamano T, et al (2010). Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci, 101, 1286-91.
  21. Orannapalai N, Attawettayanon W, Kanngern S, Boonpipattanapong T, Sangkhathat S (2014). Predicting the occurrence of cancer-associated colorectal polyp using a metabolic risk score. Mol Clin Oncol, 2, 124-8.
  22. Prolo P, Wong ML, Licinio J (1998). Leptin. Int J Biochem Cell Biol, 30, 1285-90.
  23. Riondino S, Roselli M, Palmirotta R, et al (2014). Obesity and colorectal cancer: role of adipokines in tumor initiation and progression. World J Gastroenterol, 20, 5177-90.
  24. Seoane-Collazo P, Ferno J, Gonzalez F, et al (2015). Hypothalamic-autonomic control of energy homeostasis. Endocrine, 50, 276-91.
  25. Singh SP, Kar SK, Panigrahi MK, et al (2013). Profile of patients with incidentally detected nonalcoholic fatty liver disease (IDNAFLD) in coastal eastern India. Trop Gastroenterol, 34, 144-52.
  26. Trujillo ME, Scherer PE (2005). Adiponectin--journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med, 257, 167-75.
  27. Vazzana N, Riondino S, Toto V, et al (2012). Obesity-driven inflammation and colorectal cancer. Curr Med Chem, 19, 5837-53.
  28. Wang D, Chen J, Chen H, et al (2012). Leptin regulates proliferation and apoptosis of colorectal carcinoma through PI3K/Akt/mTOR signalling pathway. J Biosci, 37, 91-101.
  29. Wei C, Ford A, Hunt L, Crowne EC, Shield JP (2011). Abnormal liver function in children with metabolic syndrome from a UK-based obesity clinic. Arch Dis Child, 96, 1003-7.
  30. Yamauchi T, Kadowaki T (2008). Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes, 32, 13-8.
  31. Zekri AR, Bakr YM, Ezzat MM, Zakaria MS, Elbaz TM (2015). Circulating levels of adipocytokines as potential biomarkers for early detection of colorectal carcinoma in Egyptian patients. Asian Pac J Cancer Prev, 16, 6923-8.
  32. Zhang L, Wen K, Han X, Liu R, Qu Q (2015). Adiponectin mediates antiproliferative and apoptotic responses in endometrial carcinoma by the AdipoRs/AMPK pathway. Gynecol Oncol, 137, 311-20.
  33. Zhang Y, Proenca R, Maffei M, et al (1994). Positional cloning of the mouse obese gene and its human homologue. Nature, 372, 425-32.

Cited by

  1. Adiponectin as Link Factor between Adipose Tissue and Cancer vol.20, pp.4, 2019,